Connect your AI

Alkermes ALKS Other Working Capital

Other Working Capital at other companies

Bristol-Myers SquibbBMY

$1.64B+54.5%

Jazz PharmaceuticalsJAZZ

-$3.9M-160%

Ionis PharmaceuticalsIONS

$7.63M+115%

Neurocrine BiosciencesNBIX

$0-100%

Arrowhead ResearchARWR

-$385K+78.2%

Rhythm Pharmaceuticals, Inc.RYTM

——

Other financials

Income statement

Revenue$392.9M+28.2%

Gross profit$331.3M+28.8%

Operating income-$48.3M-450%

Net income-$66.5M-396%

EPS (diluted)-$0.40-408%

Balance sheet

Cash & equivalents$351.6M-12.1%

Total debt$1.6B+2,034%

Total equity$1.8B+15.9%

Total assets$4.3B+105%

Cash flow

Operating cash flow-$165.7M-268%

CapEx$4.1M-59.5%

Free cash flow-$169.8M-291%

Valuation

Market cap$7.5B+9.7%

Enterprise value$8.73B+41.2%

P/E49.1×+29.7×

P/S4.8×+0.3×

Profitability

Gross margin86.6%+2.2pp

Operating margin12.3%-13.6pp

Net margin9.8%-13.5pp

FCF margin14.2%-17.6pp

Returns & leverage

Return on equity9.4%-16.1pp

Debt / equity0.9×+0.9×

Current ratio2.3×-1.1×

Where this comes from

Reported directly by Alkermes in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerAsset.

The official record: Alkermes’s 10-K, filed February 25, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alkermes's other working capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Alkermes's other working capital?: Alkermes (ALKS) reported other working capital of -$717K in Q4 2025.
How has Alkermes's other working capital changed year-over-year?: Alkermes's other working capital decreased by 135.5% year-over-year, from $2.02M to -$717K.
What does other working capital mean?: Net change in working capital items not separately classified — a residual balancing item.